RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma. Hu A, Wen X, Tian J, Wang Z, et al. Oral Oncol 2025;167:107464.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hu A, Wen X, Tian J, Wang Z, et al. RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma. Oral Oncol 2025;167:107464.
PMID: 40609408